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Abstract: The permeation properties of twenty newly synthesized α-alkoxyalkanoyl and  
α-aryloxyalkanoyl C-21 esters of standard corticosteroids: Fluocinolone acetonide, 
dexamethasone, triamcinolone acetonide and hydrocortisone were established using a 
PAMPA assay (70% silicone oil and 30% isopropyl myristate). The data were compared 
with parent corticosteroids with addition of mometasone furoate and hydrocortisone 
acetate. All newly synthesized corticosteroid C-21 esters have effective permeability 
coefficients higher then -6, mostly followed with high values of retention factors and low 
permeation. The examined compounds were grouped through relationship between 
obtained retention factors and permeation parameters (groups I–III). The classification 
confirmed group I (membrane retentions as well as permeation lower then 30%) for all 
corticosteroid standards except mometasone furoate, a potent topical corticosteroid which, 
with high membrane retention (81%) and low permeation (7.7%) fits into group III. The 
largest number of new synthesized corticosteroids C-21 esters, among them all 
fluocinolone acetonide C-21 esters, have high membrane retentions (32.4%–86.5%) and 
low permeations (1.3%–27.1%), fitting in group III. The classification was related to 
previously obtained anti-inflammatory activity data for the fluocinolone acetonide C-21 
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esters series. According to the PAMPA results the new synthesized esters could be 
considered as potential new prodrugs with useful benefit/risk ratio. 




Topical corticosteroids represent a significant group of drugs widely used in the therapy of skin 
disorders due to their anti-inflammatory and immunosuppressive actions. The applications of 
corticosteroids, especially to large areas, when the skin is injured, or under occlusive dressings may led 
to their absorption and systemic side-effects [1]. The local corticosteroids efficiency depends, at the 
first place, on their pharmacological potency and ability to be absorbed into the target epidermis and 
dermis cells [2–4]. Topical steroids can be divided into different groups due to their potencies. 
According the US classification topical corticosteroids could be classified into seven groups [5], while 
the British National Formulary suggests four classes [6]. The corticosteroids from the same group have 
similar efficiency and the similar potential to exert side effects. Thus, more potent corticosteroid 
product provides better therapeutic efficacy, but also more side effects. It is consider that the  
low-potent formulations are more suitable for application in long-term therapy, while more potent 
formulation are reserved for short time treatments and for use at areas such as the hands or soles, 
where poorly potent corticosteroids are not effective [7]. 
Drug skin penetration is an area of increasing interest in the pharmaceutical and cosmetic industries, 
but also in dermal exposure and risk assessment processes. Until today, numerous in vivo and in vitro 
test models have been introduced, particularly in drug discovery and development, to mimic the 
different biological barriers and to predict drug absorption or permeability [8,9]. Since, for in vivo 
experiments of skin penetration, either on humans or animals, ethical principles must be considered 
there was a need to establish in vitro methods/models capable for dermal absorption prediction [10,11]. 
The number of in vitro methods for evaluation drugs skin permeability employs diffusion cells which 
typically consist of human or animal skin clip [12–14]. The quantitative structure-permeability 
relationships (QSPRs) models as well as chromatographic methods such as immobilized artificial 
membrane (IAM) or biopartitioning micelar chromatography (BMC) were also applied in dermal 
absorption prediction [8,14–16], but these methodologies do not fully reflect the human  
skin properties. 
The Parallel Artificial Membrane Permeability Assay (PAMPA) is a technique developed for the 
early evaluation of passive transport permeability [17]. Depending on the nature of the artificial 
membrane, different biological barriers (intestinal or blood-brain) can be targeted [18–20]. An 
adaptation of the PAMPA technique has been recently proposed in order to mimic a percutaneous 
barrier. Until today, there are only two proposed models for high-throughput screening (HTS) 
permeability through the skin using the PAMPA method. The first model applied silicone and 
isopropyl myristate (IPM), which are not natural human skin components, as an artificial  
membrane [21,22]. The artificial membrane composed as a mixture of isopropyl myristate (30%) and 
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silicone (70%) allows prediction of human skin permeability, as well as the affinities of tested 
compounds for the stratum corneum, in a simple and rapid way [21,22]. The second model contains 
ceramide analogues, compounds similar to those present in the skin, which are responsible for the 
barrier function [23]. Although excised skin (human or animal) with its two-pathway mode of 
transport-lipophilic and hydrophilic, can be considered as the membrane of choice in permeation 
estimation, the difficulties in samples obtaining as well as the high variability of samples led to use of 
artificial membrane. PAMPA is much less labor intensive than Franz diffusion cell method using skin 
samples, but it appears to show similar predictability. One of the main limitations of PAMPA model is 
its underestimation of the compounds absorptions that are actively absorbed via drug transporters. 
Despite the limitation, PAMPA may serve as a very useful primary permeability screen during early 
drug discovery process because of its high throughput capability. 
The PAMPA process is automated and commercially available and can be used as a HTS method 
for in vitro determination of drug's skin absorption potential [24,25]. In PAMPA permeability 
measurements different detection methods can be used: UV-Vis detection, liquid chromatography 
especially coupled to MS or more recently UPLC coupled to MS detection [26–28]. 
In our recent papers the studies of solvolysis of new synthesized fluocinolone acetonide C-21 esters 
as in vitro model for predicting prodrug activation [29] and their topical anti-inflammatory  
activity [30] were reported. The aim of this study was to established membrane retentions, permeation 
parameters and effective permeability coefficients using PAMPA assay for twenty newly synthesized 
corticosteroid C-21 esters of standard corticosteroids: fluocinolone acetonide (FA), dexamethasone 
(DEX), triamcinolone acetonide (TA) and hydrocortisone (H). On the basis of PAMPA data the 
classification of investigated corticosteroid C-21 esters in comparison with standards (FA, DEX, TA, 
H with addition of mometasone furoate–MF and hydrocortisone acetate–H-21-Ac) was accomplished. 
The classification was related to previously obtained data for anti-inflammatory activity of 
fluocinolone acetonide C-21 esters. 
2. Results and Discussion 
In this paper the permeability of six standard corticosteroids (FA, DEX, TA, H, MF and H-21-Ac) 
as well as twenty newly synthesized C-21 α-alkoxyalkanoyl and α-aryloxyalkanoyl esters of FA, DEX, 
TA and H were investigated with the PAMPA test. The test was performed on an artificial membrane 
consisting of 70% silicone oil and 30% IPM, which was originally proposed by Ottaviani and 
coworkers [21,22]. This PAMPA model was applied in our study to test the membrane retention and 
membrane permeability of investigated corticosteroids using relatively fast and easy technique. These 
investigations were of importance for correlation to their local anti-inflammatory activity.  
The study was performed in triplicate and the results are presented as mean values. After the 
PAMPA tests was performed, a HPLC method was used to measure the concentrations of the 
investigated corticosteroids: the initial concentration–CD(0) in the starting solution, the residual 
concentration–CD(t) in the donor compartment (7 h after incubation) and the transferred  
concentration–CA(t) in the acceptor compartment (7 h after incubation). The assay was performed 
using the previously described HPLC method [29] with mobile phase modification for determination 
of standard corticosteroids. The mobile phase modification was introduced to achieve complete 
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separation standard corticosteroids peak from DMSO peak, which was used as cosolvent. DMSO was 
used as cosolvent with the aim of increasing the corticosteroid C-21 esters’ solubility. DMSO is one of 
the earliest and most widely studied penetration enhancers for transdermal drug delivery systems. 
On the basis of the initial (100 μM) and calculated residual and transferred concentrations according 
to peak area comparison at zero time t0, the retention factors–R and permeability coefficients–logPe of 
investigated corticosteroids were obtained. The values of R, logPe as well as permeation parameters 
CA(t)/CD(0) for standards (FA, DEX, TA, H) and their twenty corresponding C-21 esters of  
2-methoxypropionic (MPA), 2-ethoxypropionic (EPA), 2-phenoxypropionic (PhPA), 2-methoxybutyric 
(MBA) and 2-ethoxybutyric (EBA) acids obtained in PAMPA test are presented in Table 1. For the 
correlation, standard MF [31] as most efficient topical corticosteroid as well as H-21-Ac as drug 
introduced long time ago, were tested simultaneously. 
Table 1. The values of retention factors (R), permeation parameters CA(t)/CD(0) and 
permeability coefficients (logPe) obtained in PAMPA test with membrane containing 70% 
silicone oil and 30% IPM. 




















1 FA-21-MP 34.1 ± 3.5 23.1 ± 1.4 −4.64 ± 0.17 
2 FA-21-EP 45.8 ± 4.1 22.2 ± 1.6 −4.52 ± 0.19 
3 FA-21-PhP 71.9 ± 2.8 1.3 ± 0.6 −5.68 ± 0.15 
4 FA-21-MB 47.2 ± 3.4 18.0 ± 1.3 −4.65 ± 0.12 
5 FA-21-EB 72.8 ± 2.6 7.2 ± 0.9 −4.82 ± 0.10 
6 DEX-21-MP <1 23.8 ± 1.5 −4.88 ± 0.17 
7 DEX-21-EP <1 31.6 ± 0.6 −4.70 ± 0.11 
8 DEX-21-PhP 86.5 ± 4.2 4.1 ± 1.1 −4.74 ± 0.13 
9 DEX-21-MB <1 37.4 ± 1.5 −4.58 ± 0.15 
10 DEX-21-EB 11.3 ± 3.5 33.4 ± 1.2 −4.58 ± 0.13 
11 TA-21-MP 13.5 ± 4.1 38.1 ± 1.6 −4.45 ± 0.16 
12 TA-21-EP 32.4 ± 1.7 23.0 ± 1.8 −4.66 ± 0.15 
13 TA-21-PhP 51.1 ± 3.8 27.1 ± 1.4 −4.07 ± 0.14 
14 TA-21-MB 39.3 ± 4.1 16.9 ± 2.0 −4.85 ± 0.23 
15 TA-21-EB 70.1 ± 3.4 7.3 ± 1.6 −4.87 ± 0.21 
16 H-21-MP 2.6 ± 1.9 14.9 ± 1.8 −5.11 ± 0.25 
17 H-21-EP 17.2 ± 2.2 16.3 ± 1.9 −4.99 ± 0.19 
18 H-21-PhP 72.2 ± 3.1 10.6 ± 1.2 −4.58 ± 0.15 
19 H-21-MB 9.6 ± 3.2 18.5 ± 1.9 −4.97 ± 0.28 














21 FA <1 6.7 ± 1.2 −5.26 ± 0.15 
22 DEX 4.2 ± 2.0 1.3 ± 0.8 −5.99 ± 0.10 
23 TA 4.7 ± 2.3 10.8 ± 1.5 −5.01 ± 0.17 
24 H 1.5 ± 0.9 0.8 ± 0.5 −6.23 ± 0.09 
25 H-21-Ac <1 10.0 ± 1.7 −5.07 ± 0.19 
26 MF 81.0 ± 2.9 7.7 ± 1.5 −4.10 ± 0.15 
The analogous histograms of membrane retention-retention factors (R) and permeation parameters 
CA(t)/CD(0) are presented at Figure 1. The largest number of new synthesized corticosteroid C-21 
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esters showed significantly higher membrane retention in comparison with corresponding standards 
confirming that their higher lipophilicity improved the parent drugs physical and pharmaceutical 
properties that would increase benefit/risk ratio [32]. The corticosteroid C-21 esters of PhPA and EBA 
(with exception of DEX-21-EB) showed comparable R values to MF as potent (ointment) and  
mid-strength (cream)–Class 2 and Class 4, respectively [5] or Class II–potent according British 
National Formulary [6]. The same corticosteroid could belong in different classes depending on 
pharmaceutical formulation, as example of MF. 
Figure 1. The values of retention factors (R) and permeation parameters CA(t)/CD(0) of 
new synthesized C-21 esters and corticosteroid standards obtained in PAMPA test. 
 
Low values of permeation parameters are preferable and most of the C-21 esters of PhPA and EBA 
showed acceptable CA(t)/CD(0) values. Only two, DEX-21-EB and TA-21-PhP showed relatively 
higher skin permeability. In the PAMPA test results for H-21-Ac, the low membrane retention  
(R < 1%) and high permeation parameter (CA(t)/CD(0) = 10%), confirmed its classification as  
mild-Class I [6]. 
It can be seen (Table 1) that all new synthesized C-21 esters have log Pe > −6, mostly followed with 
relatively high values of retention factors (R). The classification of examined standard corticosteroids 
and the twenty new synthesized C-21 esters obtained in the PAMPA test is presented at Figure 2 
through the relationship between their retention factors, R and permeation parameters, CA(t)/CD(0). 
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Figure 2. The relationship between retention factors, R and permeation parameters, 
CA(t)/CD(0) of examined twenty new synthesized C-21 esters and standard corticosteroids 
obtained in PAMPA test. ● – standard corticosteroids; □ – twenty new synthesized  
C-21 esters.  
 
Ottaviani and coworkers [21] predicted skin permeation of numerous compounds applying a new 
membrane (70% silicone oil and 30% IPM) in the PAMPA test and presented permeate classifications 
on the basis of available literature permeability coefficients through human skin, logKp. According to 
Ottaviani and coworkers [21], permeates can be distinguished and grouped into: Permeates with a 
lower permeability coefficient, Kp (logKp < −6) having negligible membrane retention and low 
permeation (group I) and compounds with higher Kp (logKp ≥ −6) having low or negligible membrane 
retention and high permeation (group II) or having high membrane retention and low permeation 
(group III). 
The authors also confirmed [21] the good correlation (r2 = 0.81) between logKp and effective 
permeability coefficients (logPe) obtained after 7 h incubation time through 70% silicone–30% IPM 
membrane. The proposed equation for correlation between logKp and logPe for 31 investigated 
compounds was: 
logKp = (1.34 ± 0.12) logPe + (0.28 ± 0.56) (1) 
Applying this equation, in our study only the approximate logKp values could be calculated, 
indicating that corticosteroid standards (FA, DEX, TA, H, H-21-Ac) with logKp < −6 (−6.77, −7.75, 
−6.43, −8.07, −6.51, respectively) fit in group I, while only MF had logKp > −6 (−5.21). Calculated 
logKp values of the new synthesized corticosteroid C-21 esters were around −6 with the exception of 
FA-21-PhP (logKp = −7.33). The classification (Figure 2) through the relationship between retention 
factors (R) and permeation parameters (CA(t)/CD(0)) confirmed group I for corticosteroid standards 
FA, DEX, TA, H, H-21-Ac, while MF with high membrane retention (R = 81%) and low permeation  
(CA(t)/CD(0) = 7.7%) fit in group III. The results for DEX obtained in our study were in good 
accordance to previously reported data (logPe = −5.75) for this corticosteroid by Ottaviani et al. [21]. 
For group III there is a negative relationship between membrane retention (R) and permeation 
parameter CA(t)/CD(0) (high membrane retention and low permeation), indicating the membrane was a 
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trap for the investigated substances. It would be preferable that corticosteroids for local application 
belong to the group III where MF already belongs as a standard potent topical corticosteroid [31]. The 
largest number of newly synthesized corticosteroids C-21 esters (12) have high membrane retention 
(R) and low permeation [CA(t)/CD(0)], thus fitting in group III (Figure 2). According to this 
classification (group III), investigated C-21 esters could be considered as potential new prodrugs with 
useful benefit/risk ratios. 
In our previous paper [30] the anti-inflammatory activity of new fluocinolone acetonide C-21 esters 
was evaluated in the test of inhibition of croton oil induced mice ear edema (4 h after application). For 
the same group of FA C-21 esters in our recently published paper [29] it was established that the  
in vitro proposed solvolytic model, obtained by multiple regression analysis between solvolytic rate 
constant and lipophilicity with anti-inflammatory activity, could be used for prediction of prodrug 
activation. Anti-inflammatory activity [30], represented as a percentage of reduction of mass edema, 
has been determined using median effective dose ED50 (28 μM) of FA [33]. In comparison to FA 
(100%) relative anti-inflammatory activities were calculated. The best result was obtained with  
FA-21-MP (108.12%) while comparable activities were manifested by FA-21-PhP (65%) and  
FA-21-EB (60%) and the lowest activity was obtained with FA-21-EP (less than 10%). The obtained 
activity order showed a good relationship with predicted anti-inflammatory activity, which was linked 
with solvolysis rate constants (K) and lipophilicity data (cLogP values ranged from 2.79 to 4.59) of FA 
C-21 esters [29]. 
Results in the PAMPA test confirmed that all investigated FA C-21 esters (compounds 1–5) have 
high membrane retentions (R) and low permeation parameters [CA(t)/CD(0), Table 1] and fit in group 
III (Figure 2). The PAMPA results indicate a possible prolonged effect of new synthesized 
corticosteroid C-21 esters and their in vivo anti-inflammatory activities should be evaluated during at 
least 24 h in further studies. 
The major route of percutaneous transport, especially for hydrophobic molecules (such as the parent 
standard corticosteroids and the newly synthesized C-21 esters) is passive diffusion through the lipid 
matrix which can be successfully mimicked with a silicone/IPM artificial membrane in PAMPA tests. 
The data obtained in the PAMPA test designate that structural changes of parent standard 
corticosteroids (FA, DEX, TA, H) in the set of new synthesized esters would enable both, the better 




Six corticosteroid standards: fluocinolone acetonide–FA, dexamethasone–DEX, triamcinolone 
acetonide–TA, hydrocortisone–H, mometasone furoate–MF and hydrocortisone acetate–H-21-Ac and 
twenty newly synthesized corticosteroid esters: (a) FA series–fluocinolone acetonide 21-(2′-methoxy-
propionate) (FA-21-MP, 1), fluocinolone acetonide 21-(2′-ethoxypropionate) (FA-21-EP, 2), 
fluocinolone acetonide 21-(2′-phenoxypropionate) (FA-21-PhP, 3), fluocinolone acetonide 21-(2′-
methoxybutyrate) (FA-21-MB, 4) and fluocinolone acetonide 21-(2′-ethoxybutyrate) (FA-21-EB, 5); 
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(b) DEX series–dexamethasone 21-(2′-methoxypropionate) (DEX-21-MP, 6), dexamethasone 21-(2′-
ethoxypropionate) (DEX-21-EP, 7), dexamethasone 21-(2′-phenoxypropionate) (DEX-21-PhP, 8), 
dexamethasone 21-(2′-methoxybutyrate) (DEX-21-MB, 9) and dexamethasone 21-(2′-ethoxybutyrate) 
(DEX-21-EB, 10); (c) TA series–triamcinolone acetonide 21-(2′-methoxypropionate) (TA-21-MP, 11), 
triamcinolone acetonide 21-(2′-ethoxypropionate) (TA-21-EP, 12), triamcinolone acetonide 21-(2′-
phenoxypropionate) (TA-21-PhP, 13), triamcinolone acetonide 21-(2′-methoxybutyrate) (TA-21-MB, 
14) and triamcinolone acetonide 21-(2′-ethoxybutyrate) (TA-21-EB, 15); (d) H series–hydrocortisone 
21-(2′-methoxypropionate) (H-21-MP, 16), hydrocortisone 21-(2′-ethoxypropionate) (H-21-EP, 17), 
hydrocortisone 21-(2′-phenoxypropionate) (H-21-PhP, 18), hydrocortisone 21-(2′-methoxybutyrate) 
(H-21-MB, 19) and hydrocortisone 21-(2′-ethoxybutyrate) (H-21-EB, 20), were examined with 
PAMPA test. The new corticosteroid C-21 esters were synthesized as shown in Scheme 1 according to 
a previously presented procedure for the synthesis of fluocinolone acetonide C-21 esters [29] and 
characterized in our laboratory. 
Scheme 1. Synthesis of new C-21 α-alkoxyalkanoyl and α-aryloxyalkanoyl corticosteroid esters. 
 
3.2. Permeability Measurements Using the PAMPA Technique 
3.2.1. Chemicals 
The corticosteroid standard FA was purchased from Sigma Aldrich Chemie GmbH (Steinheim, 
Germany), DEX, H and H-21-Ac were purchased from Galenika a.d. (Belgrade, Serbia), TA was 
purchased from Krka (Novo Mesto, Slovenia), MF was purchased from Schering-Plough Labo  
(Heist–op–den–Berg, Belgia). DMSO (>99.7%) was purchased from Acros Organics (Chemie 
Brunschwig AG, Basel, Switzerland). Isopropyl myristate, IPM (>95%), silicone oil (DC 200),  
n-hexane (>99.5%) were purchased from Fluka Chemie GmbH (Bruch, Switzerland) while 
NaH2PO4·H2O and Na2HPO4·7H2O were from Merck (Darmstadt, Germany). Methanol Chromasolv 
HPLC purity (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and deionised water (TKA water 
purification system, Niederelbert, Germany) were used throughout this study. 
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Phosphate buffer (pH = 7) was prepared by dissolving NaH2PO4·H2O (1.167 g) and Na2HPO4·7H2O 
(3.093 g) in water (1000 mL) with the fixed total concentration of 20 mM. The 5% DMSO solution 
were prepared dissolving DMSO in phosphate buffer. The corticosteroid solutions were prepared 
dissolving the investigated corticosteroid standards as well as new synthesized corticosteroid C-21 
esters in 5% DMSO solution. The membrane solution (30% isopropyl myristate–70% silicone) was 
prepared in n-hexane (35% v/v). An aliquot of previously prepared mixture (3.5 mL, 7 mL silicone oil 
and 3 mL IPM) was transferred into a 10 mL volumetric flask, dissolved and fill up to mark  
with n-hexane. 
3.2.2. PAMPA Test 
Permeation experiments were carried out in hydrophobic PVDF 96-well filter plates (Millipore, 
Molsheim, France). Each well of the donor plate was coated with 35% (v/v) liquid membrane 
dissolved in n-hexane (17 μL) for 20 min to completely evaporate the solvent. Next, in each well of 
acceptor plate, 5% DMSO solution (400 μL) was transferred with an automatic pipette and covered by 
the donor plate, creating a PAMPA sandwich. In each well of the donor plate solutions of the tested 
corticosteroid in 5% DMSO solution (100 μM, 300 μL) was transferred by the use of an automatic 
pipette. Each substance was measured in triplicate at iso-pH conditions (the same pH value in donor 
and receptor compartment). The donor plate was covered to prevent evaporation and the whole system 
set up to interact with the vibratory mixer. After 7 h, PAMPA sandwich was removed from the mixer 
and vibration, and using the HPLC method the concentration of the investigated substances in the 
donor and receptor compartments were determined [29]. The HPLC method used was as previously 
described [29] but with some necessary modifications. A mobile phase of methanol–water (75:25 v/v) 
was used for analysis of corticosteroid C-21 esters, while the mobile phase methanol–water (50:50 v/v) 
was used for the analysis of unesterified corticosteroids to increase their retention time and prevent 
overlapping with the DMSO peak. Other HPLC parameters were as previously described. The 
concentrations of each tested corticosteroid in the appropriate time interval in the donor and acceptor 
compartments were calculated using the method of comparing the peak area of the initial concentration 
at zero time t0. 
3.3. Permeability Calculations 
The values of permeability coefficients–logPe and retention factors–R of examined corticosteroids 
were calculated using equations (2) and (3). The retention factor, R can be defined as the mole fraction 
retained in the membrane and in the microplates (i.e., filters and plate materials): 
D A A
D D D
C (t) V C (t)R 1
C (0) V C (0)
     (2) 
where CA(t)/CD(0) represents the amount of compound that reached the acceptor compartment after 
incubation time t (for VA = VD) [21]: 
D A A D A
e
LAG A D D D
2.303V V V V C (t)P log 1
A(t ) V V V (1 R) C (0)
                   
 (3) 
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The VA and VD are the volumes in the acceptor and the donor wells, respectively, A is the filter  
(0.28 cm2), multiplied by a nominal porosity of 70% according to the manufacturer, t is the incubation 
time (s), τLAG is the steady–state time (s), i.e., the time needed for the permeates concentration gradient 
to become stabilized, CA(t) is the concentration of the compound (mol·cm−3) in acceptor well at time t, 
and CD(0) is the concentration of the compound (mol·cm−3) in donor well at time 0. Steady–state time 
(τLAG) to saturate the membranes in PAMPA are relative short compared to the total permeation time 
(about 20 min with unstirred plates). 
4. Conclusions 
The topical corticosteroids’ efficiency in the first place depends on their pharmacological potencies 
and their absorption/retention into the target epidermis. The permeation of twenty newly synthesized 
corticosteroid C-21 esters in comparison with six standard corticosteroids was tested with a PAMPA 
test using a membrane containing 70% silicone oil and 30% IPM. The majority of the newly 
synthesized corticosteroid C-21 esters showed higher membrane retentions and lower permeation 
parameters than the corresponding standard corticosteroids and could be classified into group III of 
permeates.The best membrane retention with lowest permeation was displayed by the new synthesized 
corticosteroid C-21 esters of EBA and PhPA. These esters have similar permeation properties to MF, a 
potent corticosteroid standard. On the basis of PAMPA results it could be assumed that the newly 
synthesized corticosteroid C-21 esters have favourable properties exerting local anti-inflammatory 
activity in comparison with standards that would be accompanied with minimal systemic side effects 
and useful benefit/risk ratios. The data obtained in the PAMPA test as a high-throughput screening 
method indicate possible prolonged effects of the newly synthesized corticosteroid C-21 ester prodrugs. 
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